Your search for apixaban returned 104 results

The researchers searched the U.S. Medicare database for NVAF patients 65 years of age and older who were newly prescribed one of the following medications: apixaban, dabigatran, rivaroxaban, or warfarin.

Major adverse cardiopulmonary outcomes not reduced with aspirin, apixaban versus placebo for clinically stable COVID-19 outpatients

Reversal of anticoagulant activity of apixaban and rivaroxaban seen in older healthy participants

Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a new study.

For patients initiating oral anticoagulant therapy, the incidence of hospitalization for upper gastrointestinal bleeding is highest and lowest with rivaroxaban and apixaban, respectively.

Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels

Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.

No differences seen in fracture risk in head-to-head comparisons of direct oral anticoagulants

Findings seen among older patients with incident atrial fibrillation receiving warfarin or apixaban

The FDA has accepted for review a Supplemental New Drug Application (sNDA) for Eliquis (apixaban; Bristol-Myers Squibb Company and Pfizer) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE.